ABC490
Anti-BCL2A1/BFL-1 Antibody
from rabbit, purified by affinity chromatography
别名:
BCL2A1/BFL-1, Bcl-2-related protein A1, Bcl-2-like protein 5, Bcl2-L-5, Hemopoietic-specific early response protein, Protein BFL-1, Protein GRS
登录查看公司和协议定价
所有图片(2)
About This Item
UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41
生物来源
rabbit
质量水平
抗体形式
affinity isolated antibody
抗体产品类型
primary antibodies
克隆
polyclonal
纯化方式
affinity chromatography
种属反应性
human
种属反应性(根据同源性预测)
bat (based on 100% sequence homology), chimpanzee (based on 100% sequence homology), bovine (based on 100% sequence homology), Camelidae (based on 100% sequence homology)
技术
immunohistochemistry: suitable
western blot: suitable
NCBI登记号
UniProt登记号
运输
wet ice
靶向翻译后修饰
unmodified
基因信息
human ... BCL2A1(597)
一般描述
Bcl-2-related protein A1 (BCL2A1), also known as protein BFL-1, protein GRS, and Bcl-2-like protein 5 (Bcl2-L-5), is a member of the Bcl-2 family. BCL2A1/BFL-1 can interact with Bax and suppress apoptosis by inhibiting the release of cytochrome c and caspase-3 activation. BCL2A1/BFL-1 expression is reported in peripheral blood, spleen, bone marrow, lung, small intestine, and testis.
免疫原
KLH-conjugated linear peptide corresponding to the near N-terminal of human BCL2A1/BFL-1.
应用
Anti-BCL2A1/BFL-1 Antibody is an antibody against BCL2A1/BFL-1 for use in Western Blotting and Immunohistochemistry.
Immunohistochemistry Analysis: A 1:50-250 dilution from a representative lot detected BCL2A1/BFL-1 in human breast cancer and human bone marrow tissue.
质量
Evaluated by Western Blotting in human spleen tissue lysate.
Western Blotting Analysis: 1.0 µg/mL of this antibody detected BCL2A1/BFL-1 in 10 µg of human spleen tissue lysate.
Western Blotting Analysis: 1.0 µg/mL of this antibody detected BCL2A1/BFL-1 in 10 µg of human spleen tissue lysate.
目标描述
~18 kDa observed
其他说明
Concentration: Please refer to lot specific datasheet.
未找到合适的产品?
试试我们的产品选型工具.
储存分类代码
12 - Non Combustible Liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Warren Fiskus et al.
Blood cancer journal, 12(1), 5-5 (2022-01-13)
Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant (mt)-NPM1. Following MI treatment, although
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门